Radiosafe micro-computed tomography for longitudinal evaluation of murine disease models

Nathalie Berghen1,2,9, Kaat Dekoster3,4,9, Eyra Marien9, Jérémie Dabin9, Amy Hillen3,5, Jens Wouters3,4, Jasmine Deferme3,4, Thibault Vosselman3,5, Eline Tiest3,4, Marleen Lox7, Jeroen Vanobbeek8, Ellen De Langhe1,2, Ria Bogaerts5, Marc Hoylaerts7, Rik Lories1,2 & Greetje Vande Velde3,4*

Implementation of in vivo high-resolution micro-computed tomography (µCT), a powerful tool for longitudinal analysis of murine lung disease models, is hampered by the lack of data on cumulative low-dose radiation effects on the investigated disease models. We aimed to measure radiation doses and effects of repeated µCT scans, to establish cumulative radiation levels and scan protocols without relevant toxicity. Lung metastasis, inflammation and fibrosis models and healthy mice were weekly scanned over one-month with µCT using high-resolution respiratory-gated 4D and expiration-weighted 3D protocols, comparing 5-times weekly scanned animals with controls. Radiation dose was measured by ionization chamber, optical fiber radioluminescence probe and thermoluminescent detectors in a mouse phantom. Dose effects were evaluated by in vivo µCT and bioluminescence imaging read-outs, gold standard endpoint evaluation and blood cell counts. Weekly exposure to 4D µCT, dose of 540–699 mGy/scan, did not alter lung metastatic load nor affected healthy mice. We found a disease-independent decrease in circulating blood platelets and lymphocytes after repeated 4D µCT. This effect was eliminated by optimizing a 3D protocol, reducing dose to 180–233 mGy/scan while maintaining equally high-quality images. We established µCT safety limits and protocols for weekly repeated whole-body acquisitions with proven safety for the overall health status, lung, disease process and host responses under investigation, including the radiosensitive blood cell compartment.

In vivo micro-computed tomography (µCT), an excellent technique to longitudinally evaluate disease progression in small animal models, allows non-invasive visualization of different pathogenic lung processes (e.g. emphysema, fibrosis, lung infection and metastasis)1–8. To study disease progression and therapeutic effects in real-time in individual animals, consecutive scanning is essential and enables a manifold reduction in experimental animals, which is of both ethical and economical importance. Yet, the biological effects of ionizing radiation from repeated µCT scanning remain a concern, as these are largely unexplored.

Adverse radiation effects have been extensively studied for the field of radiotherapy. However, these doses (ranging from 4 to 20 Gy) and dose-rates are an order of magnitude higher than doses delivered with repetitive µCT of animal models (less than 800 mGy for a single µCT-acquisition)9–13. In healthy animals, weekly or biweekly repeated respiratory-gated µCT scans for 5 to 12 weeks were well tolerated by the animals, had no radiotoxic effects on the lungs and no interference with µCT lung read-outs10,14. However, radiosafety was never...
investigated in disease models involving rapidly dividing cells that may be differently sensitive to x-ray exposure of a \( \mu \)CT scan.

To exploit high-resolution \( \mu \)CT to its full potential and implement it in the preclinical respiratory research workflow, it is essential to investigate potential effects of repeated low-dose radiation on disease processes and host response. This is particularly relevant for radiosensitive organs such as the lungs and/or when the disease process involves rapidly dividing cells, as in many models of cancer, metastasis, inflammation and tissue remodeling. Currently, preclinical \( \mu \)CT applications focused mainly on acquiring high-resolution and -quality images while little attention was given to the delivered doses and their potential radiotoxic effects. Standard operating procedures to measure and evaluate dose and dose-effects in a preclinical setting and systematic measurements better characterizing the biological radiation effects are urgently needed. Therefore, this study assessed the effects of low-dose radiation of longitudinal whole-body \( \mu \)CT protocols on metastasis inflammation and fibrosis as well as host responses in murine models of lung disease. We aimed to establish high-quality generic \( \mu \)CT protocols that ensure safe repeated high-resolution \( \mu \)CT evaluation not interfering with animal health, the radiosensitive blood cell compartment and host response or the disease processes under investigation.

### Results

#### Repetitive 4D \( \mu \)CT in a lung metastasis model.

We investigated the potential effects of whole-body x-ray exposure from repeated \( \mu \)CT on lung metastasis disease in a syngeneic model of rapidly dividing cells. One group with induced lung metastasis (DBA/2 strain) that underwent \( \mu \)CT-scans at baseline and weekly after metastasis induction for 4 weeks, with a metastasis group that was scanned with \( \mu \)CT only at baseline and endpoint. The lung metastasis burden in both groups was monitored with weekly BLI scans. Experiment 2 compares bleomycin- (8 mice with 0.04 U and 8 mice with 0.05 U bleomycin) and sham-instilled mice (5 + 5 mice) of the C57Bl/6 strain that were weekly \( \mu \)CT-scanned with a bleomycin control group (8 mice) that was only scanned at baseline and endpoint. Experiment 3 focuses on the effect of weekly \( \mu \)CT scans without the presence of disease. Analogous to experiment 1, healthy DBA/2 mice received either only a \( \mu \)CT scan at the beginning and at the end of the experiment or weekly scans for the entire experiment duration. In experiment 4, mice (C57Bl/6 strain) scanned once are compared for delayed effects after one week with mice receiving zero scans. Experiment 5 investigates the potential effect of the low-dose 3D \( \mu \)CT protocol after 5 weekly \( \mu \)CT scans compared to one scan at the beginning and one at the end. A third control group was included that was sedated with isoflurane and handled as all other mice but did not receive any \( \mu \)CT scans. ($x$ = isoflurane, $\bigcirc$ = \( \mu \)CT scan, $\Box$ = BLI scan)

**Figure 1.** Experimental set-up. This scheme summarizes isoflurane sedation, number and timing of BLI and \( \mu \)CT scans, model induction and number of animals in each experimental group. Experiment 1 compares mice with lung metastasis (DBA/2 strain) that underwent \( \mu \)CT-scans at baseline and weekly after metastasis induction for 4 weeks, with a metastasis group that was scanned with \( \mu \)CT only at baseline and endpoint. The lung metastasis burden in both groups was monitored with weekly BLI scans. Experiment 2 compares bleomycin- (8 mice with 0.04 U and 8 mice with 0.05 U bleomycin) and sham-instilled mice (5 + 5 mice) of the C57Bl/6 strain that were weekly \( \mu \)CT-scanned with a bleomycin control group (8 mice) that was only scanned at baseline and endpoint. Experiment 3 focuses on the effect of weekly \( \mu \)CT scans without the presence of disease. Analogous to experiment 1, healthy DBA/2 mice received either only a \( \mu \)CT scan at the beginning and at the end of the experiment or weekly scans for the entire experiment duration. In experiment 4, mice (C57Bl/6 strain) scanned once are compared for delayed effects after one week with mice receiving zero scans. Experiment 5 investigates the potential effect of the low-dose 3D \( \mu \)CT protocol after 5 weekly \( \mu \)CT scans compared to one scan at the beginning and one at the end. A third control group was included that was sedated with isoflurane and handled as all other mice but did not receive any \( \mu \)CT scans. ($x$ = isoflurane, $\bigcirc$ = \( \mu \)CT scan, $\Box$ = BLI scan)
**Experiment 1: lung metastasis**

**A Weight**

|       | control | weekly |
|-------|---------|--------|
| Weight (g) | 30      | 40     |

**B BLI**

|       | control | weekly |
|-------|---------|--------|
| BLI (log) | 10      | 20     |

**C µCT-derived biomarkers**

|       | control | weekly |
|-------|---------|--------|
| µCT-derived biomarkers | 1      | 2     |

**D Blood cell counts**

|       | control | weekly |
|-------|---------|--------|
| Platelets | 1000   | 500    |
| Mean platelet volume | 10      | 20     |
| White blood cells | 10      | 20     |
| Lymphocytes | 10      | 20     |
| Neutrophils | 1000   | 500    |
| Red blood cells | 1000   | 500    |

**Figure 2.** Weekly low-dose 4D µCT does not influence the general health and disease outcomes but induces a sub-clinical decrease in white blood cell and platelet counts in a murine metastasis model. Experiment 1: weekly low-dose 4D µCT scanning of metastasis-bearing mice induces a decrease in circulating platelets, increase in mean platelet volume, decrease in red blood cells and absolute white blood cell count, due to a decrease in number of lymphocytes. (A) Mouse body weight at end point. (B) In vivo BLI signal intensity expressed as total flux (p/s) from the lung, measuring metastatic load. (C) µCT-derived biomarkers (total lung volume, aerated lung volume, non-aerated lung volume and mean lung density). (D) Selected blood cell parameters: absolute platelet cell count, mean platelet volume, white blood cell count, lymphocyte count and neutrophil count and red blood cell count. Data are presented as individual values, group mean and 95% confidence intervals. P-values are presented in the graph when p < 0.05. HU, Hounsfield units.

Furthermore, eosinophils were decreased (mean $-0.0125 \times 10^3$ cells/µL; 95% CI: $-0.0185$ to $-0.0065$), whereas number of neutrophils and red blood cells remained unaffected. In conclusion, repetitive 4D µCT-scanning influenced circulating blood cells in a lung metastasis model without clinical effects or change in disease outcomes.

**Repetitive 4D µCT in a lung inflammation and fibrosis model.** Next, repeated low-dose radiation was evaluated in a model involving endogenous rapidly dividing cells: bleomycin-induced lung fibrosis. Mice instilled with PBS or bleomycin were scanned at baseline and weekly for 4 weeks, compared with bleomycin-instilled controls only scanned at baseline and endpoint (Fig. 1).

Due to high mortality in the bleomycin groups (2 mice of 8 (weekly CT) and 3 of 8 (control) reached the endpoint), our analysis was underpowered. Therefore, we included data of an experiment with the same set-up, except that mice were instilled with a reduced dose of bleomycin (0.04 U instead of 0.05 U). All mice were weekly scanned (Fig. 3 in grey). 3 out of the 8 mice instilled with bleomycin reached the endpoint in this second cohort.

Similar to the lung metastasis model, platelet counts were decreased (mean $-182.7 \times 10^5$ cells/µL; 95% CI: $-333.8$ to $-31.62$) in the weekly scanned bleomycin group compared to control bleomycin group (Fig. 3E, Supplementary Table S2). Absolute white blood cell number was lower (mean $-2.805 \times 10^4$ cells/µL; 95% CI: $-3.277$ to $-2.334$), with less circulating lymphocytes (mean $-2.619 \times 10^3$ cells/µL; 95% CI: $-2.936$ to $-2.301$). Red blood cell numbers were also decreased (mean $-1.072 \times 10^6$ cells/µL; 95% CI: $-1.658$ to $-0.4862$). Platelet counts for PBS-instilled weekly scanned mice were similarly decreased (mean $-181.9 \times 10^5$ cells/µL; 95% CI: $-318.1$ to $-45.72$) as well as the absolute white blood cells (mean $-3.064 \times 10^3$ cells/µL 95% CI: $-3.489$ to $-2.639$) (attributed to a decrease in lymphocytes (mean $-2.776 \times 10^3$ cells/µL; 95% CI: $-3.062$ to $-2.490$)) and less red blood cells (mean $-1.586 \times 10^6$ cells/µL 95% CI: $-2.114$ to $-1.058$) were found.

Although the analysis of differences in disease severity between the bleomycin control and weekly scanned mice remained underpowered, no changes were found between these groups concerning body weight and our data indicate no clear influence from repeated scanning on mortality or pathology (extent of lung inflammation and fibrosis, assessed by histology, collagen content and µCT read-outs (Fig. 3A–D)). PBS-instilled control mice were unaffected by radiation as evaluated by histology and µCT.

In conclusion, repetitive 4D µCT-scanning lowered circulating blood cells, irrespective of disease status.

**Repeated 4D µCT in healthy mice.** To further elucidate the contribution of disease status to the effects of repeated µCT, we investigated healthy mice. One group was scanned with the weekly regime (n = 4) and the other only at beginning and endpoint (n = 4). No differences were found concerning general health and lung µCT read-outs (Fig. 4A). Similar to the findings in the two disease models, a decrease in platelets (mean $-1.586 \times 10^3$ cells/µL; 95% CI: $-2.114$ to $-1.058$) and fibrosis, assessed by histology, collagen content and µCT read-outs (Fig. 3A–D)).
**Experiment 2: lung inflammation and fibrosis**

### Figure 3. Weekly low-dose 4D μCT alters blood cell counts in a bleomycin-induced mouse model. Experiment 2: weekly-repeated 4D μCT scanning of bleomycin induced mice results in a decrease in platelets, red blood cells and a decrease in white blood cells, attributed to decreased lymphocyte counts. (A) Mouse body weight at end point (B) μCT-derived biomarkers reflecting disease progression of pulmonary fibrosis at endpoint (total lung volume, aerated lung volume, non-aerated lung volume and mean lung signal density). (C) Collagen content as measured by hydroxyproline quantification of the right lung lobes and (D) Ashcroft score of extent of fibrosis of the left lung lobes (E) selected blood cell counts: absolute platelet cell count, mean platelet volume, white blood cell count, lymphocyte count and neutrophil count and red blood cell count. Data presented as individual values, group mean and 95% confidence intervals. Grey points represent mice instilled with 0.04 U of bleomycin, other points with 0.05 U. P-values and p-adjusted values are presented in the graph when p < 0.05. HU, Hounsfield unit.

**Experiment 3: healthy**

### Figure 4. Weekly low-dose 4D μCT does not influence the general health and disease outcomes but induces a decrease in blood cell counts of healthy mice. Experiment 3: weekly low-dose 4D μCT scanning of healthy mice induces a decrease in platelets, increase in mean platelet volume, decrease in red blood cells and white blood cells, attributed to decreased lymphocyte counts. (A) μCT-derived biomarkers show no differences in healthy mice at endpoint (total lung volume, aerated lung volume, non-aerated lung volume and mean lung density). (B) Blood cell counts: absolute platelet cell count, mean platelet volume, white blood cell count, lymphocyte count and neutrophil count and red blood cell count. Data presented as individual values, group median and 95% confidence intervals. P-values are presented in the graph when p < 0.05. HU, Hounsfield unit.
−387.9 * 10^3 cells/µL; 95% CI: −521.6 to −254.3) and white blood cells (mean −0.3510 * 10^3 cells/µL; 95% CI: −0.6859 to −0.01608) (attributed to a decrease in lymphocytes (mean −0.02849 * 10^3 cells/µL; 95% CI: −0.5149 to −0.05496)) and a decrease in red blood cells (mean −1.832 * 10^6 cells/µL; 95% CI: −3.637 to −0.02679) was found in the weekly scanned healthy mice compared to controls (Fig. 4B, Supplementary Table S3). These results confirm the effect of repeated low-dose 4D µCT-scanning on circulating blood cells, irrespective of disease or inflammatory status.

To exclude that lower blood cell counts were a delayed effect of the second last scan, we compared blood cell counts of mice receiving a single scan a week before sacrifice (n = 6), and mice receiving no scan at all (n = 6).

No significant differences were found for platelets, white blood cells and lymphocytes (Fig. 5, Supplementary Table S4), indicating the observed effects in the previous experiments were indeed related to repeated exposure.

To isolate effects of repetitive x-ray exposure from potential influence of stress and anaesthesia associated with µCT, we included an additional healthy control group subjected to weekly anaesthesia and handling without µCT. This group showed no differences in blood cell counts (Fig. 6C), further confirming that blood cell count effects can be attributed to repeated x-ray exposure.
Repeated 3D µCT: image quality and circulating blood cells. To eliminate effects on blood cells, while retaining high-quality images, we optimized a 3D protocol with expiration-weighted gating but without the possibility to acquire functional data. Scan time and dose were hereby much reduced compared to retrospective respiratory-gated 4D µCT. For accurate dosimetry, we used three different methods (Table 1). Radiation dose of a single µCT scan with the 3D versus 4D protocol ranged between 180–233 mGy versus 540–699 mGy respectively.

Our 3D expiration-weighted strategy did not introduce any movement artefacts compared to respiratory-gated 4D scans. Analysis of signal-to-noise (SNR), contrast-to-noise ratio (CNR) and visual inspection confirmed equally high image quality (Fig. 7) (a mean SNR of 26.9 and 25.65 and a mean CNR of 26.13 and 24.76 for 4D and 3D protocols, respectively, defined by the Rose criterion16,17.

In healthy mice, weekly 3D µCT did not affect body weight, µCT-derived lung biomarkers nor blood cell counts (Fig. 6A–C, Supplementary Table S5); platelet numbers, white blood cells (lymphocytes as well as neutrophils) and red blood cells in weekly scanned healthy mice were not affected. In conclusion, repeated low-dose 3D µCT has no radiation effects on lungs or blood cells, while maintaining high image quality even for lung imaging in free-breathing mice.

Discussion
We investigated radiation dose and effects of repetitive whole-body µCT in different murine lung disease models and healthy mice, using a longitudinal imaging set-up typical for preclinical in vivo experiments: baseline scan, 4 weekly µCT scans for disease progression and sacrifice after last scan for ex vivo read-outs. Using a low-dose 4D retrospective respiratory-gating protocol, we observed no effects of repetitive scanning on disease outcomes in

|                      | Low-dose 4D µCT protocol | Low-dose 3D µCT protocol |
|----------------------|---------------------------|--------------------------|
| IC in air            | 540 mGy                   | 180 mGy                  |
| TLDs in phantom     | 699 mGy                   | 233 mGy                  |
| RL probe in phantom | 585 mGy                   | 195 mGy                  |

Table 1. Dose measurements for the low-dose 4D and 3D µCT protocols. Dose measurements were performed with ionization chamber (IC) in air, thermoluminescent detectors (TLDs) in mouse phantom and optical fiber radioluminescence (RL) probe in mouse phantom as specified in materials and methods.
mice with lung metastasis, lung inflammation and fibrosis or healthy mice, but detected a decrease in circulating blood platelets and lymphocytes. With a 3D expiration-weighted scanning protocol, reducing the radiation dose by two-thirds, this effect could be eliminated whilst retaining equally high imaging quality.

We analysed both healthy and diseased DBA/2 and C57Bl/6 mice, commonly utilized strains in preclinical pulmonary research. As we used immunocompetent mice, we can conclude that μCT has the potential to study disease processes where host response is an important factor, with C57Bl/6 mice in particular susceptible to lung fibrosis. As we did not observe nor quantify an effect of radiation after weekly 4D μCT in healthy animals, our results are in line with previous studies reporting the absence of radiation-induced lung or cardiac damage in healthy mice scanned weekly for 5 to 12 weeks. Furthermore, we assessed different lung disease models involving rapidly dividing exogenous and endogenous cells in immunocompetent mice. Repetitive μCT had no influence on disease progression in mice with progressing lung metastases. In mice with lung inflammation and fibrosis, our data also indicate no clear influence from repeated scanning on fibrosis, although this experiment was underpowered. Repeated low-dose 4D μCT can therefore be considered safe for the animal and disease process under investigation, even when involving rapidly dividing cells, but we continue to recommend the use of a similarly radiation exposed control group.

We next investigated whether repeated low-dose x-ray exposure may still have subtle effects on more radiosensitive processes by analysing circulating blood cells since the hemopoietic system and lymphocytes in particular are very sensitive to radiotoxicity. In repetitively scanned mice, we observed less (but larger) circulating platelet and lymphocyte counts, neutrophils remained unaffected. Red blood cells numbers were lowered in repetitively scanned healthy and bleomycin-induced C57Bl/6 mice, but not in DBA/2 mice with or without metastasis. The lower platelet and lymphocyte counts after repeated radiation in mice with lung metastasis, fibrosis and in healthy mice, points to disease-independent effect of the cumulative points to dose. The decrease in platelets is likely sub-clinical, since we detected no bleeding problems. Also a murine platelet reduction up to 70% is reported not to result in clinical effects. Defining values of clinically significant lymphopenia is more difficult, given the high variability in reported murine reference values. The lymphocyte reduction could be sub-clinical, not affecting the immune system, given the absence of infections or a correlation with disease outcomes in our study. Yet, we cannot formally exclude minimal effects on immune system functionality. Importantly, we nevertheless saw no influence of the decreased platelets and lymphocytes on the studied disease processes.

We examined blood cell counts immediately after the last scan (typical set-up of last scan followed by sacrifice and ex vivo work-up). Therefore, results reflect the short-term effect of cumulated radiation from weekly repeated μCT scans, no conclusions can be drawn on long-term effects and potential recuperation with time. Noteworthy, blood cell changes were not an effect of the last scan, since control groups received the same endpoint scan. No changes were seen one week after a single scan, ruling out delayed effects of the second-last scan. Moreover, no differences in circulating blood cells were observed comparing μCT-scanned healthy mice to controls that were sedated but never scanned. Therefore, we conclude that effects result from the cumulative radiation exposure.

To design longitudinal μCT protocols without radiotoxicity and still considering breathing movement corrections, we developed a respiration-weighted 3D protocol. This could lower the radiation dose per scan with two-thirds while maintaining the same lung image quality as the 4D protocol, with no increased movement artefacts, but without the possibility to extract functional lung read-outs (e.g. tidal volume, readouts at inspiration). This 3D protocol is nevertheless useful for most studies, where volume data from inspiratory phase are not needed. With this 3D protocol, we could eliminate all previously found radiation effects on blood cell counts, thereby offering a generally applicable longitudinal μCT protocol with demonstrated safety for the animal and (patho-)physiological processes under investigation. Our results further expand knowledge about maximum acceptable repeated dose exposure, as previous reports found no blood cell count changes in C57Bl/6 mice scanned less frequently (every other week for 3 times), as well as in mice scanned more frequently (3 times/week for 4 weeks), but with markedly lower radiation doses than our 3D protocol (reported dose 16.19 mGy measured at phantom center versus 180–233 mGy dose).

Indispensable in guarding over radiation exposure is awareness of dose exposure and hence accurate dosimetry. As currently no standard operating procedures exist for preclinical μCT dosimetry, we measured radiation dose of our 4D and 3D μCT protocols by three different methods: IC in air, in-phantom TLDs and an in-phantom RL probe. The doses measured in-phantom were higher compared to in-air, as expected due to the contribution of scattered x-rays. The IC is the reference and used for calibration of TLDs and RL probe. Nevertheless, size limits its use in μCT, since its dimensions do not enable complete dose profile measurements and the closed lead shielding may hamper insertion of an IC in the field-of-view during scanning. Moreover, the interest of using such IC combined with a mouse phantom is limited in contrast with conventional CT in the clinical context where the dimensions of the IC are negligible compared to those of the CT Dose Index phantoms. TLDs are a practical alternative. Although their energy response is not as good as the IC, they are made of tissue-equivalent material and small enough to be inserted in-phantom. An inherent limitation of TLDs is they do not allow real-time dosimetry, needed during preclinical in vivo scan parameter optimization. Compared to TLDs, the RL probe results are subject to higher uncertainty because of the higher energy dependence of the RL material. Nevertheless, the advantages for μCT are its small size and capacity to perform online and real-time measurements, useful for scan protocol optimization.

To summarize, it is necessary and within our potential to design high-quality and safe μCT protocols, regarding the murine health status, disease process and host responses under investigation. We have established an upper dose limit to be delivered with repeated μCT scanning: a dose of 540–699 mGy delivered weekly for 5 times, can be considered as physiologically safe with a sub-clinical drop in circulating blood cell counts, while a dose of 180–233 mGy per single scan delivered under the same longitudinal regime is safe in absolute terms. More specifically, our results indicate the possibility to design high-resolution μCT protocols without influence on the
most radiosensitive processes in the body, thereby ideal to study (lung) disease processes and host responses in rodent models.

Materials and Methods

Animals. Mice were kept in individually ventilated cages or filter top cages with free access to food and water in a conventional animal facility. The syngeneic mouse model of lung metastasis was induced by tail vein injection of cells from the squamous cell carcinoma (SCC) lung cancer cell line KLN205 (10^6 cells in 200 μl PBS) in 8-week-old male C57Bl/6 mice (Janvier, Le Genest, France) and 8-week-old female DBA/2 mice under transient isoflurane (2% in oxygen) gas anaesthesia (Envigo, Venray, The Netherlands)\(^1\). For the bleomycin-induced lung inflammation and fibrosis model, 8-week-old male C57Bl/6 mice (Janvier, Le Genest, France) were anaesthetised with a mixture of ketamin (Nimatek 10 mg/ml, Europet, Gemert-Bakel, The Netherlands) and xylazine (2% Xyl-M 1 mg/ml, VMD, Arendonk, Belgium). Via a tracheotomy, 50 μL of Bleomycin (0.04 U or 0.05 U, Sanofi-Aventis, Diegem, Belgium) or vehicle phosphate buffered saline (PBS, Lonza, Basel, Switzerland) for sham controls was instilled\(^2,3\). Mouse body weights were recorded at baseline and at least once weekly until sacrifice. For experiments conducted with healthy animals, 8-week-old female DBA/2 or male C57Bl/6 mice (Janvier, Le Genest, France) were used. An overview of the number of animals per experimental group can be found in the experimental set-up (Fig. 1). European, national and institutional guidelines for animal welfare and experimental conduct were followed (The KU Leuven Ethical Committee for animal research approved all experiments: p039/2014, p037/2017 and p227/2013).

Bioluminescence imaging. For BLI and quantification of lung metastasis burden, an IVIS Spectrum system (CaliperLS; Perkin-Elmer, Hopkinton, MA, USA) was used with software provided by the manufacturer (Living Image version 4.4.17504). D-luciferin (in PBS, 126 mg/kg) was injected intraperitoneally. Acquisition of consecutive frames was started immediately thereafter until maximum signal intensity was reached, measured as photon flux per second through a region of interest (2.9 cm × 1.8 cm) covering the lungs. Image acquisition numbers and times varied between 10 and 15 frames of 30–60 s each, depending on optimal acquisition settings as a function of signal intensity intrinsic to lung metastasis grade.

Micro-computed tomography. Mice were anesthetized by isoflurane (1.5–2% in oxygen, Piramal Healthcare, Morpeth, Northumberland, United Kingdom) and scanned in supine position using in vivo μCT (Skyscan1278, Bruker micro-CT, Kontich, Belgium) with following parameters: 50 kVp X-ray source voltage, 918 μA current, 1 mm aluminium X-ray filter, 55 ms exposure time per projection, acquiring projections with 0.9° increments over a total 220° angle, 10 cm field of view covering the whole body producing reconstructed data sets with 50 μm isotropic voxel size either with (‘4D protocol’) or without retrospective respiratory gating (‘3D protocol’). For the 4D protocol, images were acquired in list mode, with nine projections per view, logged simultaneously with the breathing cycle of the mouse and retrospectively time-based sorted, resulting in four reconstructed 3D data sets corresponding to four different breathing cycle phases (4D) (end-inspiratory, end-expiratory and two intermediate phases). 3D datasets were acquired without respiratory gating using similar settings as above, acquiring and averaging three projections per view.

Software provided by the manufacturer (TSort, NRecon, DataViewer, and CTan) was used to retrospectively gate, reconstruct, visualize, and process μCT data\(^35\). For Hounsfield unit (HU) calibration, a phantom of an air-filled 1.5 mL tube inside a water-filled 50 mL tube was scanned. Based on full stack histograms of a volume-of-interest (VOI) containing only water or air, the mean grayscale index of water (93) set at 0 HU and grayscale index of air (0) at -1000 HU. Quantification of mean lung density (in HU), non-aerated lung volume, and total lung volume was carried out for a VOI covering the lung, comprising of regions of interest that were manually delineated on the coronal μCT images, thereby avoiding heart and main blood vessels. The threshold to distinguish aerated from non-aerated lung tissue volume, manually set at −287.5 HU, was kept constant for all data sets.

Dosimetry. The radiation dose of an in vivo μCT scan was experimentally assessed with (1) an ionization chamber, (2) an optical fiber radioluminescence (RL) probe and (3) thermoluminescent detectors (TLDs) in a mouse phantom.

A Farmer-type ionization chamber FC65-G (IBA, Schwarzenbruck, Germany) was positioned in air at the centre of the gantry, only supported by a piece of tape placed on the top of the examination bed.

Ten MCP-N thermoluminescent detectors (TLD) (LiF:Mg, Cu, P material, Institute of Nuclear Physics, Krakow, Poland), were inserted in as many dedicated cavities in the centre of a cylindrical polymethyl methacrylate phantom (100 mm long, 20 mm diameter). The phantom was positioned at the centre of the gantry on the examination bed. Reported dose is the average over the 10 positions.

The optical fiber radioluminescence (RL) probe was inserted in the centre of a dedicated cylindrical polymethyl methacrylate phantom (100 mm long, 20 mm diameter); position of the phantom in the gantry was identical to the position of the TLD phantom.

The ionization chamber was calibrated free in air in a RQR3* reference field\(^36\) at the second-standard calibration laboratory of the Belgian Nuclear Research Centre (Mol, Belgium). The TLDs and the RL probe were calibrated in air against the ionization chamber using the LD3 beam quality.

μCT image quality. Contrast-to-noise ratio (CNR) and signal-to-noise ratio (SNR) are based on the average pixel value of the heart and calculated according to the following equations:
Blood cell counts. Blood obtained by cardiac puncture at sacrifice, mixed with sodium citrate 3.8%, was analysed using a Cell-dyn 3700 (Abbott, Illinois, USA). Supplementary Tables S1–S5 show all analysed parameters.

Histopathology. Formalin-fixed and paraffin-embedded lung sections were stained with haematoxylin-eosin. Pulmonary fibrosis was scored using the semi-quantitative Ashcroft score27. Collagen content was assessed by hydroxyproline quantification on the right lung lobes (experiment 2), as previously described28.

Statistical analysis. All measurements are reported as individual value, mean and 95% confidence intervals (CI). Data were analysed using GraphPad Prism 7.0a (Graphpad Software Inc, San Diego, CA). Based on prior work and the nature of the biological data a normal distribution was assumed. Residuals and QQ graphs were used for visual assessment of the distribution. Where of interest, groups were compared by t-test or one-way ANOVA with Bonferroni corrected multiple comparisons. Resulting differences between the means are reported with 95% confidence intervals and exact p-values.
24. Miyahara, N. et al. Evaluation of X-ray doses and their corresponding biological effects on experimental animals in cone-beam micro-CT scans (R-mCT2). *Radiol Phys Technol* **9**, 60–68, https://doi.org/10.1007/s12194-015-0334-1 (2016).

25. Vande Velde, G. D. L. E., Poelmans, J., Dresselaers, T., Lories, R. J. & Himmelreich, U. Magnetic resonance imaging for noninvasive assessment of lung fibrosis onset and progression: cross-validation and comparison of different magnetic resonance imaging protocols with micro-computed tomography and histology in the bleomycin-induced mouse model. *Invest Radiol* **49**, 691–698 (2014).

26. Commission, I. E. Medical diagnostic X-ray equipment-radiation conditions for use in the determination of characteristics. *IEC* **61267** (2005).

27. Ashcroft, T., Simpson, J. M. & Timbrell, V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. *Journal of Clinical Pathology* **41**, 467, 10.1136/jcp.41.A.467 (1988).

28. Woessner, J. F. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. *Archives of Biochemistry and Biophysics* **93**, 440–447, https://doi.org/10.1016/0003-9861(61)90291-0 (1961).

**Acknowledgements**

This research was supported by KU Leuven Internal Funds (C24/17/061 & STG/15/024). NB and KD received a PhD fellowship from the Flemish research foundation FWO (11ZP518N, 1S77319N).

**Author contributions**

G.V.V. conceived the study; N.B., K.D., E.D.L., R.B., M.H., R.L. and G.V.V. designed the experiments. N.B., K.D., E.M., J.D., T.V., E.T., M.L., R.B. and G.V.V. performed the experiments. N.B., K.D., J.D., T.V. and E.T. analyzed the data. M.H., E.D.L., R.L. and G.V.V. supervised the experiments and data analysis. N.B. and K.D. wrote the manuscript. J.V., R.L. and G.V.V. reviewed the manuscript. All authors have read and approved the final manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-53876-x.

Correspondence and requests for materials should be addressed to G.V.V.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019